Total Payments
$8,213
2023 Payments
$40.67
Companies
6
Transactions
15
Payment Breakdown by Category
Research$8,090 (98.5%)
Food & Beverage$123.36 (1.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,090 | 7 | 98.5% |
| Food and Beverage | $123.36 | 8 | 1.5% |
Payments by Type
Research
$8,090
7 transactions
General
$123.36
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,434 | 4 | $0 (2018) |
| Allergan Inc. | $656.00 | 3 | $0 (2017) |
| ABBVIE INC. | $64.29 | 5 | $0 (2023) |
| Intuitive Surgical, Inc. | $26.31 | 1 | $0 (2023) |
| Ethicon US, LLC | $19.25 | 1 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $13.51 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $40.67 | 2 | Intuitive Surgical, Inc. ($26.31) |
| 2022 | $37.89 | 3 | ABBVIE INC. ($37.89) |
| 2021 | $12.04 | 1 | AbbVie Inc. ($12.04) |
| 2019 | $19.25 | 1 | Ethicon US, LLC ($19.25) |
| 2018 | $6,654 | 2 | Eli Lilly and Company ($6,654) |
| 2017 | $1,449 | 6 | Eli Lilly and Company ($779.70) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: NEUROSCIENCE | ||||||
| 02/14/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: SURGERY | ||||||
| 06/09/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: NEUROSCIENCE | ||||||
| 05/26/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: NEUROSCIENCE | ||||||
| 04/14/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: NEUROSCIENCE | ||||||
| 12/08/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2019 | Ethicon US, LLC | LINX Reflux Management System (Device) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Endo-Mechanical | ||||||
| 12/11/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $3,658.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 03/19/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | In-kind items and services | $2,996.39 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 09/26/2017 | Eli Lilly and Company | — | — | In-kind items and services | $165.30 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | ||||||
| 08/28/2017 | Eli Lilly and Company | — | — | In-kind items and services | $614.40 | Research |
| Study: A PHASE 3, LONG-TERM, OPEN-LABEL SAFETY STUDY OF LY2951742 IN PATIENTS WITH MIGRAINE | ||||||
| 08/01/2017 | Sunovion Pharmaceuticals Inc. | UTIBRON (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: RESPIRATORY | ||||||
| 03/07/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $356.00 | Research |
| Study: A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | ||||||
| 03/07/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $175.00 | Research |
| Study: A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | ||||||
| 03/07/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $6,654 | 2 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $656.00 | 3 |
| A PHASE 3, LONG-TERM, OPEN-LABEL SAFETY STUDY OF LY2951742 IN PATIENTS WITH MIGRAINE | Eli Lilly and Company | $614.40 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | Eli Lilly and Company | $165.30 | 1 |
About Dr. Thomas Ledbetter, M.D
Dr. Thomas Ledbetter, M.D is a Internal Medicine healthcare provider based in Waxahachie, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760426092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Ledbetter, M.D has received a total of $8,213 in payments from pharmaceutical and medical device companies, with $40.67 received in 2023. These payments were reported across 15 transactions from 6 companies. The most common payment nature is "" ($8,090).
Ad
Practice Information
- Specialty Internal Medicine
- Location Waxahachie, TX
- Active Since 06/16/2006
- Last Updated 06/04/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1760426092
Products in Payments
- TRULICITY (Drug) $6,654
- UBRELVY (Drug) $37.89
- QULIPTA (Drug) $26.40
- Da Vinci Surgical System (Device) $26.31
- LINX Reflux Management System (Device) $19.25
- UTIBRON (Drug) $13.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Waxahachie
Dr. Bilal Jalil, Md, MD
Internal Medicine — Payments: $12,937
Internal Medicine $12,937
Sharon Choi
Internal Medicine — Payments: $4,850
Internal Medicine $4,850
Dr. Fawad Tufail, Md, MD
Internal Medicine — Payments: $2,680
Internal Medicine $2,680
Oday Alhafidh, M.d, M.D
Internal Medicine — Payments: $2,669
Internal Medicine $2,669
William Wise, D.o, D.O
Internal Medicine — Payments: $2,301
Internal Medicine $2,301
Yolanda Brady, M.d, M.D
Internal Medicine — Payments: $1,986
Internal Medicine $1,986